MedWatch

Is William Demant Invest seeking hostile takeover of GN? Three scenarios in play

William Demant Invest has extended its equity position in GN Store Nord to at least 10%, and whereas the Danish investment firm’s CEO says this move is wholly in line with company strategy, several analysts question the motives behind the purchase.

Photo: Henrik Kastenskov

William Demant Invest (WDI), majority shareholder of hearing health company Demant, has set something in motion rarely seen on Nasdaq Copenhagen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs